Together, our data suggest that PARP inhibition may accelerate the resolution of TB lung disease when used in combination with effective antibiotics by reducing neutrophil recruitment, CD4+ T cell responses, and lung fibrosis, thus antagonizing granuloma formation or maintenance. The gene discussed is PARP1; the disease is lung disorder.